WBR0902: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
{{WBRQuestion | {{WBRQuestion | ||
|QuestionAuthor={{Rim}} | |QuestionAuthor={{Rim}} (Reviewed by Serge Korjian) | ||
|ExamType=USMLE Step 1 | |ExamType=USMLE Step 1 | ||
|MainCategory=Pharmacology | |MainCategory=Pharmacology | ||
Line 21: | Line 21: | ||
|MainCategory=Pharmacology | |MainCategory=Pharmacology | ||
|SubCategory=General Principles | |SubCategory=General Principles | ||
|Prompt=A researcher is investigating the effects of two drugs A and B on blood pressure in rats. The graph below shows the maximal effect of A in decreasing blood pressure when administered alone or when administered in combination with B. | |Prompt=A researcher is investigating the effects of two drugs A and B on blood pressure in rats. The graph below shows the maximal effect of A in decreasing blood pressure when administered alone or when administered in combination with B. Which of the following combinations has similar pharmacodynamics curve to that of A and B combined? | ||
[[File: | [[File:WBR0902.png|450px]] | ||
|Explanation=Efficacy is defined as the maximal effect a drug can produce. While a full agonist produces maximal effect, a partial agonist only | |Explanation=Efficacy is defined as the maximal effect a drug can produce. While a full agonist produces a maximal effect, a partial agonist can only produce a fraction of that effect i.e. has a lower efficacy. The figure demonstrates that when A is administered alone, a maximal response is observed. However, when A and B are combined, the curve is shifted downwards signifying a decrease in efficacy. The dose response curve demonstrates that the response reaches a plateau and does not increase despite an increase in the dose of drug A. This is the classical effect of a non-competitive inhibitor causing an irreversible decrease in efficacy. Phenoxybenzamine is a non-competitive inhibitor of norepinephrine that fits the dose-response curve displayed. | ||
|AnswerA=[[Naloxone]] and [[morphine]] | |AnswerA=[[Naloxone]] and [[morphine]] | ||
|AnswerAExp=Naloxone is a competitive antagonist of morphine. When a competitive antagonist is present, the potency of the agonist is altered and the curve of the effect of the agonist by increasing dose will be shifted towards the right. | |AnswerAExp=Naloxone is a competitive antagonist of morphine. When a competitive antagonist is present, the potency of the agonist is altered and the curve of the effect of the agonist by increasing dose will be shifted towards the right. |
Revision as of 20:25, 9 March 2015
Author | [[PageAuthor::Rim Halaby, M.D. [1] (Reviewed by Serge Korjian)]] |
---|---|
Exam Type | ExamType::USMLE Step 1 |
Main Category | MainCategory::Pharmacology |
Sub Category | SubCategory::General Principles |
Prompt | [[Prompt::A researcher is investigating the effects of two drugs A and B on blood pressure in rats. The graph below shows the maximal effect of A in decreasing blood pressure when administered alone or when administered in combination with B. Which of the following combinations has similar pharmacodynamics curve to that of A and B combined? |
Answer A | [[AnswerA::Naloxone and morphine]] |
Answer A Explanation | AnswerAExp::Naloxone is a competitive antagonist of morphine. When a competitive antagonist is present, the potency of the agonist is altered and the curve of the effect of the agonist by increasing dose will be shifted towards the right. |
Answer B | [[AnswerB::Atropine and acetylcholine]] |
Answer B Explanation | AnswerBExp::Atropine is a competitive antagonist of acetylcholine. When a competitive antagonist is present, the potency of the agonist is altered and the curve of the effect of the agonist by increasing dose will be shifted towards the right. |
Answer C | [[AnswerC::Haloperidol and dopamine]] |
Answer C Explanation | AnswerCExp::haloperidol is a competitive antagonist of dopamine. When a competitive antagonist is present, the potency of the agonist is altered and the curve of the effect of the agonist by increasing dose will be shifted towards the right. |
Answer D | [[AnswerD::Ondansetron and serotonin]] |
Answer D Explanation | AnswerDExp::Serotonin is a competitive antagonist of ondansetron. When a competitive antagonist is present, the potency of the agonist is altered and the curve of the effect of the agonist by increasing dose will be shifted towards the right. |
Answer E | [[AnswerE::Noreprinephrine and phenoxybenzamine]] |
Answer E Explanation | AnswerEExp::Phenoxybenzamine is a noncompetitive inhibitor of norepinephrine. An increase in the concentration of norepinephrine is not able to overcome the effect of phenoxybenzamine . |
Right Answer | RightAnswer::E |
Explanation | [[Explanation::Efficacy is defined as the maximal effect a drug can produce. While a full agonist produces a maximal effect, a partial agonist can only produce a fraction of that effect i.e. has a lower efficacy. The figure demonstrates that when A is administered alone, a maximal response is observed. However, when A and B are combined, the curve is shifted downwards signifying a decrease in efficacy. The dose response curve demonstrates that the response reaches a plateau and does not increase despite an increase in the dose of drug A. This is the classical effect of a non-competitive inhibitor causing an irreversible decrease in efficacy. Phenoxybenzamine is a non-competitive inhibitor of norepinephrine that fits the dose-response curve displayed. Educational Objective: |
Approved | Approved::Yes |
Keyword | WBRKeyword::Antagonist, WBRKeyword::competitive antagonist, WBRKeyword::non-competitive antagonist, WBRKeyword::phenoxybenzamine, WBRKeyword::Norepinephrine |
Linked Question | Linked:: |
Order in Linked Questions | LinkedOrder:: |